Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 103 of 114, showing 5 Applications out of 569 total, starting on record 511, ending on 515

# Protocol No Study Title Investigator(s) & Site(s)

511.

ECCT/25/08/05   Floral roll over study
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Dr. Isaac Tsikhutsu
Site(s) in Kenya
1. KEMRI WALTER REED KERICHO (Kericho county)
2. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrudes Childrens Hospital (Nairobi City county)
5. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
7. KEMRI Kondele Children\'s Hospital (Kisumu county)
 
View

512.

ECCT/22/02/01   An Open label Inclacumab study
    An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Fredrick Asirwa Chite
3. Videlis N nduba
4. Prof Jessie N Githanga
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
3. KEMRI/CRDR (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
5. Gertrude’s Children’s Hospital. (Nairobi City county)
6. Strathmore University Medical Centre (Nairobi City county)
 
View

513.

ECCT/22/04/01   GBT Open Label inclacumab Ph3
    An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Fredrick Asirwa Chite
3. Prof Jessie N Githanga
4. Videlis N Nduba
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. International Cancer Institute (ICI)-Eldoret (Uasin Gishu county)
3. KEMRI/CRDR (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
5. Gertrude’s Children’s Hospital. (Nairobi City county)
 
View

514.

ECCT/22/08/01   GBT Open Label inclacumab Ph3
    An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial   
Principal Investigator(s)
1. Prof Jessie N Githanga
2. Bernhards Ragama Ogutu
3. Fredrick Asirwa Chite
4. Videlis N Nduba
Site(s) in Kenya
1. Gertrude’s Children’s Hospital (Nairobi City county)
2. Strathmore University Medical Centre (Nairobi City county)
3. International Cancer Institute (ICI)-Eldoret (Uasin Gishu county)
4. KEMRI/CRDR (Nairobi City county)
5. KEMRI Siaya Clinical Research Annex (Siaya county)
 
View

515.

ECCT/16/05/01   A5338
    A5338   An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among   Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz   (EFV) in Women Co-Infected with Human Immunodeficiency Virus (HIV) and   Tuberculosis (TB)   
Principal Investigator(s)
1. David Schnabel
Site(s) in Kenya
KISUMU CRS
 
View